Jennison Associates
LBRX

Jennison Associates’s LB Pharmaceuticals LBRX Stock Holding History

Jennison Associates’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6M Buy
540,902
+2,686
+0.5% +$78.9K 0.01% 348
2026
Q1 		$13.3M Sell
538,216
-283,636
-35% -$6.54M 0.01% 359
2025
Q4 		$18.3M Buy
821,852
+82,812
+11% +$1.45M 0.01% 349
2025
Q3 		$11.7M Buy
+739,040
New +$11.7M 0.01% 363

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Jennison Associates's LBRX Position: Q2 2026 in Review

Jennison Associates increased its LB Pharmaceuticals (LBRX) stake by 0.5% in Q2 2026, buying an estimated $78.9K and bringing the position to 540,902 shares worth $17.6M. The position accounts for 0.01% of the portfolio, ranked #348.

Jennison Associates first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.3M in Q4 2025. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Jennison Associates held 540,902 shares of LB Pharmaceuticals worth $17.6M as of Q2 2026.
  • Jennison Associates bought 2,686 LB Pharmaceuticals shares in Q2 2026, an estimated $78.9K.
  • LB Pharmaceuticals made up 0.01% of Jennison Associates's portfolio in Q2 2026, its #348 holding.
  • Jennison Associates first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Jennison Associates's LB Pharmaceuticals position peaked at $18.3M in Q4 2025.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.